Novo Nordisk A/S’ (NYSE:NVO) stock is trading higher on Friday as the Wegovy (semaglutide) pill hit 3,071 U.S. prescriptions in the first four days after its launch, Reuters noted, citing IQVIA data.

Performance Data

Wegovy pill showed an average weight loss of about 17% (16.6%) when used along with a reduced-calorie diet and exercise, and if all patients stayed on treatment, compared to about 3% (2.7%) for placebo.

The weight loss pill was approved in December 2025.

The market ‍is closely watching early sales for signs of strength or weakness.

United Kingdom’s Approval

Also on Friday, the Medicines and Healthcare products Regulatory Agency (MHRA) approved a maximum dose of up to 7.2mg per week of Wegovy (semaglutide).

In November 2025, Novo Nordisk submitted its supplemental marketing application to the U.S. Food and Drug Administration (FDA) for a higher dose of semaglutide injection 7.2 mg for chronic weight management.

Under the Commissioner’s National Priority Voucher (CNPV) expedited program, ...